Generic Name: Levetiracetam
Brand Name: pdp-levETIRAcetam
Manufacturer: Pendopharm, a division of Pharmascience Inc.
Manufacturer Requested Reimbursement Criteria1: For patients on levetiracetam that cannot intake solid oral tablets.
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule C
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input open||June 17, 2020|
|Call for patient input closed||August 07, 2020|
- No patient input submission received
|Submission received||July 17, 2020|
|Submission accepted||August 05, 2020|
- Submission was not accepted for review on 31 Jul 2020
- Revised category 1 requirements received on 31 Jul 2020
|Review initiated||August 06, 2020|
|Draft CADTH review report(s) provided to sponsor for comment||October 27, 2020|
|Deadline for sponsors comments||November 05, 2020|
|CADTH responses on draft review report(s) provided to sponsor||November 27, 2020|
|Expert committee meeting (initial)||December 09, 2020|
|Draft recommendation issued||December 21, 2020|
December 23, 2020